🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

57 results for “Nanjing” Clear

  1. LCAR-AMDR Cells Product

    Nanjing Legend Biotech Co.

    Acute Myeloid Leukemia

    phase 1 mab terminated

    1 trial

  2. LCAR-B4822M CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 1 small molecule active

    1 trial

  3. LCAR-BCDR cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab terminated

    1 trial

  4. LCAR-BCX cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  5. LCAR-C182A cells

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab terminated

    1 trial

  6. LCAR-C18S cells

    Nanjing Legend Biotech Co.

    Solid Tumors, Adult

    phase 1 mab terminated

    1 trial

  7. LCAR-G08 cells

    Nanjing Legend Biotech Co.

    Advanced Gastrointestinal Tumors

    phase 1 mab terminated

    1 trial

  8. LCAR-HL30 cells

    Nanjing Legend Biotech Co.

    Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  9. LCAR-M23 cells

    Nanjing Legend Biotech Co.

    Epithelial Ovarian Cancer

    phase 1 mab terminated

    1 trial

  10. LUCAR-20S CAR-T cells

    Nanjing Legend Biotech Co.

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  11. LUCAR-20SP cells

    Nanjing Legend Biotech Co.

    Relapsed B-cell Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  12. LUCAR-B68 cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  13. LUCAR-DKS1 NK cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  14. LUCAR-G39D cells product

    Nanjing Legend Biotech Co.

    B-Cell Non-Hodgkin Lymphoma-Recurrent

    phase 1 mab active

    1 trial

  15. LUCAR-G79 T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  16. LUCAR-G79D T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  17. LVIVO-TaVec400 product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)

    phase 1 mab active

    1 trial

  18. NTQ5082 capsule

    Nanjing Chia-tai Tianqing Pharmaceutical

    Complement-mediated Hemolytic Diseases

    phase 1 small molecule active

    1 trial

  19. RJK-RT2831 dose-escalation phase Ia

    Nanjing Zenshine Pharmaceuticals

    Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  20. TQB2101 for Injection

    Nanjing Zenshine Pharmaceuticals

    Advanced Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  21. anti-CD123 CAR-T treatment

    Nanjing Legend Biotech Co.

    Acute Leukemia

    phase 1 small molecule terminated

    1 trial

  22. Dexamethasone

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Localized Primary Osteoarthritis of Both Hips (Diagnosis)

    approved small molecule active

    1 trial

  23. Hepatitis B vaccine

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Hepatitis B Vaccination, HIV

    approved mab active

    1 trial

  24. Normal Saline

    Nanjing Zenshine Pharmaceuticals

    Breast Feeding

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources